Tryptase and IL-33 in Bronchoalveolar Lavage Fluid May Predict the Types of Eosinophilic Pneumonia and Disease Recurrence.


Journal

International archives of allergy and immunology
ISSN: 1423-0097
Titre abrégé: Int Arch Allergy Immunol
Pays: Switzerland
ID NLM: 9211652

Informations de publication

Date de publication:
2022
Historique:
received: 07 05 2021
accepted: 12 10 2021
pubmed: 25 11 2021
medline: 6 4 2022
entrez: 24 11 2021
Statut: ppublish

Résumé

Eosinophilic pneumonia (EP) is characterized by a marked accumulation of eosinophils in the lungs and blood. Eosinophils and mast cells play an important role in the pathogenesis of EP via release of biomarkers such as tryptase and interleukin (IL)-33. However, the potential role of these biomarkers is not fully understood. We aimed to evaluate the differences among the levels of tryptase and IL-33 in bronchoalveolar lavage fluid (BALF) from several types of EP. We evaluated the differences between the levels of these biomarkers in the recurrent and nonrecurrent cases. We prospectively collected the clinical data of patients with EP, diagnosed between 2006 and 2015 in our institution. Bronchoscopy was performed before steroid treatment; BALF was collected. The clinical characteristics of EP patients and the levels of tryptase and IL-33 in BALF were evaluated. We enrolled 15 patients with chronic EP (CEP), 5 with acute EP (AEP), 10 with drug-induced EP, and 6 with angiitis-related EP. Tryptase levels in the CEP group were significantly higher than that in the drug-induced EP group (p = 0.048), while the AEP group had the highest IL-33 levels. Recurrence of EP was noted in 67% of patients with CEP. The levels of tryptase and IL-33 were notably higher in the recurrent cases than that in the nonrecurrent CEP group (p = 0.004, p = 0.04, respectively). Furthermore, there was a positive correlation between the levels of tryptase and IL-33 in the BALF of patients with CEP (ρ = 0.69, p = 0.004). Tryptase and IL-33 in BALF are useful biomarkers for the assessment of EP types. These biomarkers could be used to predict disease recurrence.

Identifiants

pubmed: 34818650
pii: 000520180
doi: 10.1159/000520180
doi:

Substances chimiques

IL33 protein, human 0
Interleukin-33 0
Tryptases EC 3.4.21.59

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

415-423

Informations de copyright

© 2021 S. Karger AG, Basel.

Auteurs

Tomohiro Akaba (T)

Department of Respiratory Medicine, Tokyo Women's Medical University, Tokyo, Japan, akaba.tomohiro@twmu.ac.jp.

Mitsuko Kondo (M)

Department of Respiratory Medicine, Tokyo Women's Medical University, Tokyo, Japan.

Kaori Hara (K)

Department of Respiratory Medicine, Tokyo Women's Medical University, Tokyo, Japan.

Rie Mizobuchi (R)

Department of Respiratory Medicine, Tokyo Women's Medical University, Tokyo, Japan.

Kazuhiro Abe (K)

Department of Respiratory Medicine, Tokyo Women's Medical University, Tokyo, Japan.

Azusa Miyoshi (A)

Department of Respiratory Medicine, Tokyo Women's Medical University, Tokyo, Japan.

Osamitsu Yagi (O)

Department of Respiratory Medicine, Tokyo Women's Medical University, Tokyo, Japan.

Etsuko Tagaya (E)

Department of Respiratory Medicine, Tokyo Women's Medical University, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH